Efficacy of Haploidentical Allogeneic Hematopoietic Cell Transplantation following Two Courses of Venetoclax and Azacytidine Therapy in Patients over 55 Years Old with Acute Myelogenous Leukemia
AML patients over 55 years of age who received haplo-HSCT after two courses of VEN/AZA therapy had outcomes similar to those who received haplo-HSCT after intensive chemotherapy, suggesting that two courses of VEN/AZA therapy as a bridge to haplo-HSCT are feasible for patients over 55 years old.
Authors
- Junjie Cao (ORCID: https://orcid.org/0000-0001-5570-9007)
- Xiaohong Du
- Dong Chen (ORCID: https://orcid.org/0000-0002-8904-9307)
- Xuhui Liu (ORCID: https://orcid.org/0000-0002-6460-6787)
- Shuangyue Li (ORCID: https://orcid.org/0000-0003-2897-4205)
- Ying Lu (ORCID: https://orcid.org/0000-0001-9031-3999)
- Danjie Luo
- Renzhi Pei
- Xianxu Zhuang
Institutions
- Ningbo University (CN)
Publication Details
- Journal
- Acta Haematologica
- Published
- 2024-10-25
- DOI
- https://doi.org/10.1159/000542034
- Citations
- 2
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.91